A Phase I, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of MEK162 in Subjects With Mild, Moderate and Severe Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 15 Mar 2017
Price : $35 *
At a glance
- Drugs Binimetinib (Primary)
- Indications Liver failure
- Focus Pharmacokinetics
- Sponsors Array BioPharma; Novartis
- 09 Mar 2017 Status changed from recruiting to discontinued.
- 30 Jan 2017 Planned primary completion date changed from 1 Nov 2016 to 31 Mar 2017.
- 30 Sep 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Nov 2016.